In the Phase 2 study of patients with chronic kidney disease, the highest dose of the drug lowered by 86% the levels of ...

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 20, 2025 /PRNewswire/ -- Equity Insider News Commentary - The World Economic ...

From surgical precision tools to real-time diagnostics, brain-responsive stimulation, and multi-disease detection systems, AI ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Surgeons in southern California successfully completed the world's first-ever human bladder transplant on 41-year-old Oscar ...

Researchers say they have discovered the first drug mechanism that binds to the pyrin domain to block NLRP3 and prevent a series of reactions resulting in inflammation.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Some women may be unaware they're living with risks for heart disease, kidney disease and metabolic conditions like diabetes, which drive risk for cardiovascular disease. The interplay among these ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.